Kenvue Inc.
- Branche
- Household & Personal Care
- Börse
- USA
- Land / Region
- USA
- Börsengang
- 4. Mai 2023
- Mitarbeiter
- 21.780
- Website
- www.kenvue.com
Zusammengesetzter Bewertungsbereich · konservativ $10–$13 / fair $16–$20 / optimistisch $22–$26. Bei $18.12, Innerhalb des fairen Bereichs des inneren Werts.
Bei Veröffentlichung $17.69 (28. Mai 2026)
Noch keine Analysen zu dieser Aktie in Ihrer Sprache.
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.
Geschichte
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
Branchenposition
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
